In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.34, indicating a +1.21% shift from the ...

Cathie Wood's Ark Genomic Revolution ETF owns $50 million worth of Recursion Pharmaceuticals stock.

Some of the industry’s most closely-watched AI drugs could provide insight into the success of technology-assisted ...

Full of paradoxes, humor, and heart, these sci-fi books are perfect for anyone missing the time travel antics of the Back to ...

Cathie Wood's exchange-traded funds (ETFs) ended June by selling $11.2 million worth of stock in synthetic DNA manufacturer ...

Intactis Bio joins the Biocomputing industry, which seeks to deliver lower-energy, cost-efficient computing capacity driven ...

Cathie Wood's ARK Invest's largest purchase during the last week by value was Elon Musk's Space Exploration Technologies ...

The new "Claude Science" from Anthropic uses artificial intelligence to tackle rare genetic disorders and tropical maladies, ...

Demis says the web will change significantly into an agent-first web. AI agents won’t need human-style visual renders and ...